Endius: Waiting for the Revolution in Spine

Though tiny in a field dominated by huge companies, Endius believes it can hold sway in the niche of minimally invasive spine surgery, where it claims two key advantages: a single platform that enables spine surgeons to do 80% of the things they already do without changing open surgical techniques, and clinical advantages over open. Now Endius needs partnerships to gain complementary products for its access systems as well as relationships with surgeons. These allliances may not necessarily follow the traditional model of allying with a giant company for its distribution muscle. Endius might rather forge alliances with other small companies.

By Mary Stuart

Intractable back pain is one of those problems for which the cure is often worse than the disease. After spine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By 

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.